Michael Dickinson Highlights Outcomes and CNS Relapse Patterns in High-Grade B-Cell Lymphoma - Oncodaily

News|Articles|October 20, 2026 In a phase 1 trial, CD19/CD20/CD22 CAR T cells produced complete responses in 83% of patients with relapsed/refractory B-cell non-Hodgkin lymphoma. A trispecific chimeric antigen receptor (CAR) T-cell product targeting CD19, CD20, and CD22 with an OX40 costimulatory domain was safely administered to patients with relapsed/refractory B-cell malignancies, with particularly encouraging activity in B-cell non-Hodgkin lymphoma (B-NHL), according to results from a first-in-human phase 1 trial (NCT05418088) published in Blood Cancer Discovery. Successful manufacturing was achieved in 16 of 17 patients, with 1 failure occurring in a heavily pretreated patient with Richter transformation. The median manufacturing time was 7 days (range, 6-10), the median transduction efficiency was 38.8% (range, 16.9%-57.6%), and the median fold expansion was 5.4 (range, 1.4-12.9). No dose-limiting toxicities (DLTs) were observed across the 3 dose levels tested. Cytokine release syndrome (CRS) occurred in 25% of patients and was limited to grade 1 or 2, with a median onset of 8.5 days after infusion.

AJMC news storyOncologic factors, not HIV viral suppression status, determine how well people with HIV fare after a lymphoma diagnosis, according to a retrospective cohort study published in HIV Medicine. Lymphoma has remained one of the most common cancers in people with HIV since the earliest years of the epidemic, and that risk has persisted even as antiretroviral therapy (ART) transformed HIV from a fatal illness into a manageable chronic condition. A 2024 protocol published in BMJ Open, outlining a planned systematic review to quantify that excess burden worldwide, noted that people with AIDS face roughly 400 times the risk of high-grade non-Hodgkin lymphoma (NHL) and about 15 times the risk of low-grade NHL compared with the general population. Because ART has sharply reduced AIDS-defining malignancies, clinicians have debated whether virologic control should factor into how aggressively to treat a lymphoma, or whether oncologic staging and histology alone should drive therapy.

Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin lymphoma (NHL), accounting for approximately 20% to 25% of NHL diagnoses in Canada. Approximately 2,400 to 3,000 Canadians are diagnosed with FL each year. Follicular lymphoma is difficult to treat and often returns.1,2 Although treatment can control the disease, follicular lymphoma is generally considered incurable, with patients typically experiencing repeated relapses and progressively shorter remissions over time.3

Adults who have survived Hodgkin lymphoma for at least 5 years may face significantly elevated long-term health risks and cancer and noncancer mortality, according to a new study led by researchers at The University of Texas MD Anderson Cancer Center. The retrospective population-based study, published in JAMA Network Open, was led by Bryan Valcarcel, MD, Instructor, and Luis Malpica Castillo, MD, Associate Professor, both of the Department of Lymphoma & Myeloma at MD Anderson. The researchers analyzed data from 2000 to 2017, including more than 20,000 survivors of Hodgkin lymphoma with an average age of 36 years. Eligible patients were 20 years and older at the time of their initial diagnosis of Hodgkin lymphoma. They reported 2,899 deaths occurred among survivors, whereas in the general population 1,481 deaths would have been expected. While the majority of deaths were related to cancer, noncancer adverse health conditions also were increased in the survivors of Hodgkin lymphoma.

Although alcohol abstinence is associated with improved health outcomes, addiction researchers have theorized that brain changes that occur during abstinence may increase a person’s risk of relapse. To explore this theory, we studied how mice behaved after giving them long-term voluntary access to alcohol followed by a forced abstinence period. We found that a subset of the mice developed aversion-resistant alcohol intake – that is, they now drank alcohol despite the quinine we added to make it increasingly bitter. Moreover, compared to those who did not experience forced abstinence, these mice drank even larger quantities of the very bitter alcohol. These results suggest there are potential bodily challenges associated with abstinence that contribute to relapses in alcohol use disorder.